Linezolid Krka

Linezolid, the active ingredient in Linezolid Krka, is an oxazolidinone presented as an oral tablet for systemic use. It treats serious bacterial infections caused by resistant Gram‑positive organisms in both adult and pediatric patients.\n\nGNH India supplies Linezolid Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is an antibacterial agent indicated for infections caused by resistant Gram‑positive bacteria.\n\nMethicillin‑resistant Staphylococcus aureus (MRSA) infections: provides effective bacterial eradication in skin, soft‑tissue and systemic disease.\nVancomycin‑resistant Enterococcus (VRE) infections: offers a therapeutic option when other agents fail.\nCommunity‑acquired pneumonia: treats pneumonia caused by susceptible pathogens.\nSkin and soft‑tissue infections: resolves cellulitis, abscesses and wound infections.\nComplicated intra‑abdominal infections: combats mixed aerobic and anaerobic organisms in the abdomen.

Linezolid may cause a range of adverse reactions, from mild to serious.\n\nCommon Side Effects:\n- Nausea: mild to moderate gastrointestinal upset.\n- Diarrhea: loose stools, often self‑limiting.\n- Headache: transient cranial discomfort.\n- Vomiting: occasional emesis.\n- Metallic taste: altered taste perception.\n\nSerious or Rare Side Effects:\n- Thrombocytopenia: significant drop in platelet count requiring monitoring.\n- Peripheral neuropathy: sensory changes with prolonged use.\n- Serotonin syndrome: risk when combined with serotonergic agents.\n- Lactic acidosis: rare metabolic disturbance.\n- Optic neuropathy: vision changes, may be irreversible.

Use of Linezolid requires careful clinical assessment and monitoring.\n\nRenal impairment: monitor renal function and adjust therapy as needed.\nHepatic impairment: assess liver enzymes before and during treatment.\nConcomitant serotonergic drugs: avoid due to risk of serotonin syndrome.\nProlonged therapy: perform regular complete blood counts to detect hematologic toxicity.\nPregnancy: safety unknown; use only if benefits outweigh risks.\nStore at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Linezolid can interact with several drug classes, necessitating vigilance.\n\nMajor Interactions (Avoid):\n- Selective serotonin reuptake inhibitors (SSRIs): may precipitate serotonin syndrome.\n- Monoamine oxidase inhibitors (MAOIs): increase risk of hypertensive crisis and serotonin toxicity.\n- Tyramine‑rich foods: can cause hypertensive episodes when combined with linezolid.\n\nModerate Interactions (Monitor Closely):\n- Rifampin: induces metabolism, reducing linezolid plasma levels.\n- Warfarin: may enhance anticoagulant effect, requiring INR monitoring.\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase bleeding risk, especially with thrombocytopenia.